Introduction

53
The Department of Veterans Affairs (VA) initiated the Million Veteran Program (MVP) in 2011 to 54 create a mega-biobank of at least one million samples with genetic data linked to nationally 55 consolidated longitudinal clinical records 1 . The initial and continuing goal of MVP is to create a national 56 resource for research to improve the health of United States Veterans and, more generally, to 57 contribute to our understanding of human health. MVP has currently collected samples from over 58 800,000 Veteran participants and with continued recruitment efforts expects to exceed a total of 1 59 million participants in the next 2 to 3 years. 60
While MVP is similar in some respects to other large biobank projects such as the UK Biobank, 61
the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH), the China 62 Kadoorie Biobank (CKB), and the DiscovEHR initiative 2-4 , it is unique in several ways. MVP is one of the 63 largest single biobanking efforts to date, satisfying the need for larger genetic datasets while also 64 benefiting from a very rich, nationally integrated longitudinal clinical database housed in the largest 65 consolidated healthcare network in the United States. This feature allows for enhanced clinical 66 phenotyping capabilities. The availability of additional self-reported health and lifestyle survey 67 information augments clinical data from the Veterans Information Systems and Technology Architecture 68 (VistA) -the VA's Electronic Health Record (EHR) . 69 Furthermore, with over 29% of participants self-reporting non-white ethnicity, MVP has 70 substantial diversity in genetic ancestry, meeting a pressing need for greater diversity in genome-wide 71 association analyses to discover novel associations, reduce false positives, and increase research equity 5-72 8 . As such, the MVP cohort provides an unprecedented opportunity for increasing the power of genome-73 wide association studies (GWAS) and will enable association discoveries for clinically important low 74 frequency and rare variants possible only in larger sample sizes. Reliable typing of these variants may 75 provide explanations of missing genetic susceptibility in complex or non-Mendelian diseases. However, 76 the genetic diversity of MVP also poses challenges in genotype quality control. 77
In this report, we introduce the first installment of MVP genotype data consisting of 459,777 78 samples surveyed at 668,418 markers. In brief, we 1) describe the design of a research genotyping array 79 with emphasis on clinically useful and/or rare variants applicable to multi-ethnic backgrounds; 2) 80 describe the generation and quality control of genotyping data; 3) highlight some of the unique features 81 of the current MVP dataset, including exploratory analyses of genetic ancestry; and 4) replicate effect 82 sizes of previously reported variants associated with height in European Americans and African 83
Americans. Overall, we find that the MVP genetic dataset, linked to deep phenotypic data, is a high-84 quality and diverse resource for performing genetic analyses. 85
Materials and Methods
86
Human subjects and data and sample collection 87 The VA Central Institutional Review Board (IRB), as well as the local IRBs at the VA Boston 88
Healthcare System and the VA Connecticut Healthcare System, approved this project. An overview of 89 the recruitment strategies and protocols is given in a previous publication 1 . Briefly, participants were 90 recruited from approximately 60 VA healthcare facilities across the United States on a rolling basis. 91
Informed consent was obtained from all participants. Participants consented to a blood draw and to 92 have their DNA analyzed, as well as to linking their genetic information with their full clinical, survey and 93 other health data. Participants were also invited to answer two separate surveys about basic 94 demographic information and lifestyle characteristics. 95
Blood drawn from consenting participants was shipped to the central biorepository in Boston, 96 Massachusetts where DNA was extracted and later shipped to two external vendors for genotyping on a 97 custom Axiom® array designed specifically for MVP (MVP 1.0) . A description of the MVP 1.0 array design 98 features is detailed in Supplementary Materials. 99
Thermo Fisher Scientific (formally Affymetrix) Axiom® Genotyping Platform 100
The MVP 1.0 custom Axiom® array is based on the Axiom® Genotyping Platform. The Axiom 101 genotyping platform utilizes a two-color, ligation-based assay using 30-mer oligonucleotide probes 102 synthesized in situ onto a microarray substrate. Each single nucleotide polymorphism (SNP) feature 103 contains a unique oligomeric sequence complementary to the genomic sequence flanking the 104 polymorphic site on either the forward or the reverse strand. Solution probes bearing attachment sites 105 for one of two dyes depending on the 3' (SNP-site) base (A or T, versus C or G) are hybridized to the 106 target complex, followed by ligation for specificity. Oligonucleotide sequences complementary to the 107 forward or reverse strands are referred to as probesets. A marker (SNP or indel) can be interrogated by 108 the forward and/or reverse strand probeset. 109
For additional details of the Axiom® Genotyping Platform, see the Supplemental Materials and 110
Methods. 111
Genotype calling 112 We received unprocessed Axiom® genotype data for 485,856 unique samples assayed by two 113 vendors, referred to as Vendor 1 and Vendor 2, and performed genotype calling in batches grouped by 114 vendor and sample processing date. Using data provided by the vendors and generated from our 115 internal genotype calling process (see Supplemental Materials and Methods for details), we first 116 analyzed the standard Axiom® genotype quality metrics and compared these metrics between the two 117 vendors. 118
After calling genotypes, we applied an advanced normalization procedure for mitigating plate-119 to-plate variation developed in collaboration with ThermoFisher Scientific Inc. The procedure was 120 applied selectively on a per-batch basis to probesets exhibiting high plate-to-plate variance. After plate 121 normalization, we applied standard marker quality control procedures to clean and harmonize genotype 122 calls across all the batches (Supplemental Materials and Methods), followed by advanced sample QC. 123 124   Sample contamination   125 To detect and mitigate sample contamination, we assessed heterozygosity with PLINK, version 126 1.9, by calculating the F coefficient and quarantining samples with an F coefficient of less than -0.1. We 127 assessed excess relatedness by using the relatedness inference software KING, version 2.0, and 128 quarantined samples having a kinship coefficient of at least 0.1 with 7 or more other samples within 129 MVP. These samples had high dish QC (DQC) and low call rates and were outliers compared to the 130 majority of samples in the MVP dataset ( Figure S5D ). Because a call rate below 98.5% correlated with 131 excess sample heterozygosity or relatedness, we removed samples (15,436, or 3 .00%) with call rates 132 below this threshold 9 . All samples that were removed or quarantined from the current release of MVP 133 data will be re-genotyped and included in the future data releases. 134 Sample mislabeling 135 We identified samples and plates demonstrating potential mislabeling issues by analyzing 136 genotype concordance between intentional duplicate samples that were sent blinded to the vendors as 137 new samples for genotyping. Of the 25,867 intentional duplicate pairs, only 211 (0.82%) pairs were 138 highly discordant (greater than 1% discordance). Samples on plates with discordant intentional duplicate 139 pairs were quarantined for further analysis and re-genotyping. We also removed both samples and 140 plates if the duplicate pair had a relatedness coefficient of less than 0.45. These precautions were taken 141 due to the concern of potential plate swaps and led to 9,975 samples being quarantined. 142
Advanced sample QC
Sample misidentification 143
To discriminate between misidentified intentional duplicates (same samples intentionally 144 genotyped twice), technical duplicates (controls repeatedly genotyped by vendors), and monozygotic 145 twins, we calculated sample relatedness with the KING software, version 2.1 10 . Monozygotic twins were 146 confirmed by cross-referencing EHR data. Pairs with birth dates differing by no more than one day and 147 having unique participant identifiers and first names were considered verified monozygotic twin pairs. 148
Unverified samples were quarantined as potentially mislabeled and will be re-genotyped. 149
Sex check 150
To confirm sample gender, we extracted markers genotyped on the X chromosome while 151 excluding the pseudoautosomal region, used the sex-check command from PLINK, and compared the 152 expected F coefficient on the X chromosome to the gender recorded in the sample's EHR for all 153 samples 11 . Participants whose reported gender differed from that inferred by PLINK were quarantined 154 from subsequent analysis. We also removed remaining samples on plates with 4 or more gender 155 mismatches to account for potential plate swaps. The threshold is relatively low because of the low 156 percentage of females in our dataset. 157
Advanced marker QC
158
Advanced marker QC pipeline 159 We implemented three main approaches to create the advanced marker QC pipeline: (1) 160 exclude probeset calls from all batches for probesets that failed advanced QC tests; (2) exclude probeset 161 calls in a given batch for which the probeset is not recommended; and (3) choose the best probeset per 162 marker for markers interrogated by multiple probesets, and exclude probesets calls from all batches for 163 the "not-best" probesets. Details of each steps of the advanced marker QC are available in Supplemental 164
Materials and Methods and in Figure S4 , Figure S6A , and Figure S7A . 165
The advanced marker QC pipeline produced an inclusion list of probesets that met quality 166 standards across the entire MVP dataset. For each batch, we included a probeset in the dataset if it met 167 all three criteria: 1) included in the inclusion list; 2) recommended in that batch; and 3) was the best 168 probeset for a marker interrogated by multiple probesets. We then generated a list of probesets per 169 batch, created PLINK marker list binary files for each batch, and then merged all batches together using 170 the PLINK merge command. 171
Reproducibility of genotype calling 172
To assess the consistency of genotype calls across time and vendors, we analyzed the 173 discordance between 25,867 intentional duplicate samples that were sent to the vendors blinded. After 174 confirming these sample pairs were genetically identical through KING relatedness inference, we 175 determined the number of minor allele pairs (MAPs) for each marker. A MAP is any pair of genotypes for 176 a marker where both pairs are called and the pair contains at least one minor allele. We then calculated 177 the number of discordant genotyping pairs per MAP for each marker. Normalizing by the number of 178 MAPs renders different MAF bins comparable in the discordance calculation. Otherwise, rare markers 179 will always have extremely low discordance rates, as most samples carry the homozygous major 180 genotype. 181
Additionally, within the 485,856 samples genotyped in the MVP cohort, we included 2,064 182 positive control samples. We called the genotypes of the positive controls along with other MVP 183 samples across 112 batches organized by genotyping scan date for 668,418 markers passing advanced 184 marker quality control. These genotypes were compared to the consensus positive control genotype. 185
To construct the consensus genotype sequence, we calculated the frequency of each marker 186 across the panel of 2,064 positive control samples. Markers with MAF of less than 1% were set to 187 homozygous in the consensus sequence, and markers with MAF of greater than 49% were set to 188 heterozygous in the consensus sequence. For markers with MAF greater than or equal to 1% and less 189 than or equal to 49% (536, or 0.082% of markers) or that had no observed calls (18,158, or 2.76%), we 190 set the consensus genotype to missing. 191 We calculated concordance across all common (MAF ≥ 5%) and low frequency (MAF < 5%) 192 markers, where MAFs were assessed over the entire MVP sample. We then calculated concordance 193 between the consensus sequence and each positive control. Concordance was defined as the number of 194 matching called genotypes over the total number of called genotypes. Uncalled markers in either the 195 positive control or the consensus sequence were not included in either the numerator or the 196 denominator of the concordance calculation. We then plotted the concordance distribution for each 197 batch's positive controls across time. 198 Comparing MVP allele frequencies to those from gnomAD and UK Biobank between the UK Biobank and MVP were matched using SNP rsIDs. Since information on marker 207 chromosome, genomic positions, reference allele, and alternate allele were not provided in the 208 summary statistics, we were unable to check for swapped alleles. However, we expect variant 209 annotation in MVP and the UK Biobank to be well harmonized as both were genotyped on Axiom® 210 arrays and following the same standard Axiom® marker QC workflow. 211
For this analysis, European Americans (EA) were defined as samples with greater than 0.9 GBR 212 proportion based on ADMIXTURE results (described below), resulting in a sample size of 311,365. We 213 used PLINK to compute allele frequencies by genetic ancestry subgroup via "--freq" using default filters 214 and quality control parameters. 215 216 We performed additional preprocessing of the MVP dataset before performing the genetic 217 relatedness analysis. We applied standard PLINK 1.9 filters for genotype missingness (>5% removed), 218 MAF (<1% removed), and sample missingness (>5% removed) 11 . We then conducted pairwise 219 relatedness inference using KING 2.1 to identify related pairs 10 . KING explicitly accounts for population 220 structure and is therefore an appropriate algorithm for our sample, which contains diverse genetic 221 ancestry. However, KING is also known to overestimate relatedness in the presence of recent admixture. 222 Therefore, we selected SNPs with low load in PCs 1-3 for a second round of KING as in the UK Biobank 12 . 223
Genetic relatedness
The first round of KING was run with the command "--related --degree 3" to identify all potential 224 pair of individuals with closer than 3rd degree relatedness. From this result, we excluded all individuals 225 with more than 200 3rd degree relatives and also families with more than 100 members as suspected 226 sample processing artifacts such as low-level sample contamination. Then, a set of unrelated individuals 227 was defined using the largest_independent_vertext_sets() function in the Python version of the igraph 228 tool. Principal component analysis (PCA) was then conducted with the unrelated samples. Only SNPs 229 with greater than 0.01 MAF and less than 0.015 missingness were considered for this PCA. 23 regions of 230 high LD defined in the UK Biobank 18 were also excluded, and then SNPs were pruned using an R 2 231 threshold of 0.1, window of 1000 markers, and step size of 80. In the end, 90,288 SNPs were selected for PCA, which was conducted using PLINK v2.00a2LM with the command "--pca var-wts approx" to obtain 233 variant weights and fast PCA approximation. Low weight SNPs in PC1, PC2, and PC3 were selected by 234 adjusting the absolute weight threshold to keep at least two thirds of the input SNPs which led to 60,118 235 SNPs being put forward for the next round of KING. 236
The second round of KING was again conducted with the command "--related --degree 3". The 237 effect of using SNPs with low weights in PCs 1-3 on the distribution of number of relatives per individual 238 is shown in Figure S10 A-B. We flagged 35 individuals with more than 200 3 rd degree relatives (UK 239
Biobank reported 9 individuals with more than 200 3 rd degree relatives), as well as all members of two 240 clusters that were tightly interconnected with each other (Supplemental Materials and Methods and 241 Figure S10 C-D, Figure S11 ). 242
We defined genetically identical pairs as those having a kinship coefficient of 0.45 or greater 243 (the maximum kinship coefficient output by KING is 0.5). However, given the large number of intentional 244 duplicates samples in our dataset, we only considered genetically identical pairs as monozygotic twin 245 pairs after cross-referencing EHR data as above. Parent-child pairs were defined as those having a 246 kinship coefficient of greater than or equal to 0.19 and less than 0.45 and having less than 0.0025 247 percent of the genome held with zero alleles identical-by-state (IBS0). Sample pairs with a kinship 248 coefficient greater than or equal to 0.19 and less than 0.45 and IBS0 greater than or equal to 0.0025 249 were designated full siblings. Any pairs of participants with a kinship coefficient between 0.0884 and 250 0.19 were inferred to be second-degree or third-degree relatives. To identify potential trios in our 251 sample, we extracted parent-child pairs in which a sample appears twice. We then assessed the kinship 252 coefficient between the other two participants. If the other two participants were not a related pair and 253 consisted of one male and one female, we identified these three samples as a trio. 254
Genetic ancestry 255
For genetic ancestry analysis, we used the same set of markers used for relatedness analysis and 256 applied LD pruning with PLINK (--indep-pairwise 1000 50 0.05), which left us with 50,000 markers. 257
Principal component analysis 258
For 1000 Genomes Project projection PCA, we merged the MVP dataset with the 1000 Genomes 259
Project Phase 3 reference panel 13 . The 1000 Genomes Project dataset was first filtered to ensure 260 scalable merging with the MVP dataset. Markers with MAF less than 1% and any samples constituting 261 related pairs were removed prior to LD pruning with PLINK using the same parameters as above. We 262 then calculated PCs using the 1000 Genomes Project dataset and projected the MVP samples onto them 263 using EIGENSOFT, version 6.0.1 14 . 264 We also calculated the PCs on the filtered MVP dataset alone using the FastPCA method from 265 the EIGENSOFT package for within-cohort PCA. For this PCA, we excluded all related individuals, whereas 266 we kept all related individuals in the 1000 Genomes project PCA. 267 S8C). Participants with more than 80% of their genetic ancestry attributed to one reference population 276 were assigned to that reference. Remaining participants who had greater than 90% of their genetic 277 ancestry derived from two reference populations were assigned to that pair of populations. Any 278 participants not meeting the above two criteria were assigned to a separate subgroup (MVP_OTHER) 279 and were assumed to contain admixture from three or more reference populations. 280 UMAP analysis 281 We used Uniform Manifold Approximation Projection (UMAP), a dimensionality reduction 282 method that is useful for visualizing both global and local structure in data, to further visualize the 283 genetic ancestry of the MVP cohort. A UMAP embedding was calculated based on the first 10 principal 284 components of unrelated samples using hyperparameters n_neighbors of 15 and min_distance of 0.1, 285 which were suggested by a previous study on UK Biobank data 16 . We then visualized the population 286 structure by projecting subpopulations identified by our ADMIXTURE analysis onto the UMAP 287 embedding. 288
ADMIXTURE analysis
GWAS of Height
289
Height measurements, dates of measurement, dates of birth for each participant were extracted 290 from the VA healthcare system's EHR. Any height measurement outside the range of 48 to 84 inches was 291 excluded 17 , and inches were converted to meters. Age at measurement was calculated by subtracting 292 the date of birth from the date of height measurement. Individuals younger than 18 or older than 120 293 years old were excluded. Sex was genetically determined sex by PLINK. 294
Markers whose genotype missingness was greater than 1%, as well as non-autosomal markers, 295 were removed. Samples whose missingness was over 5% were also excluded. Using the results of the 296 relatedness analysis described below, we also removed all closely related pairs. 297
After marker and sample filtering, we ran association tests using BOLT-LMM 18 with sex, age, age-298 squared and the first 10 PCs as covariates. LD scores were calculated from the 1000 Genomes Project population subsets using ldsc 1.0 19 . Model SNPs were generated using PLINK 2.0 by pruning unrelated 300 samples with an R-squared threshold of 0.2 (--pairwise-indep 1000 50 0.2). Principal components (PCs) 301 were also generated using PLINK 2.0 (--pca approx) on the cohorts that had model SNPs extracted. 302
We extracted the effect size, direction of effect, and allele for each previously associated marker 303 from the GWAS catalog on March 21, 2019 and then extracted the effects for the markers present in the 304 MVP association analysis. We then scaled the effect values within each study to between 0 and 1 to 305 account for different height units and plotted the previously derived effects against those inferred in 306 MVP. 307
Results
308
The MVP 1.0 Array (Table S1) Figure S3 is an overview of the steps taken to ensure high quality genotype data for the MVP 327 cohort. Advanced genotype and sample QC were conducted in addition to the standard Affymetrix good 328 practice guidelines and are described in Materials and Methods and Supplemental Materials and 329 Methods. In addition, we further devised a batch variation correction step to apply to markers that 330 showed significant allele frequency differences between releases (Supplemental Methods and Figure S4 , 331 Figure S6A ). 332
We investigated multiple quality control metrics for across and within the two assay vendors. 333
Median Axiom® DQC values for all genotyping batches were greater than 95 for either vendor (Figure  334 S5A). Median QC call rate was also high, exceeding 99% for each genotyping batch (Figure S5 B-C 
Marker and sample QC and selection 339
The MVP 1.0 array contains a large amount of novel, custom marker content that has not been 340 validated on other arrays. These markers were assayed with more than one probeset, requiring 341 advanced marker QC to determine which probesets for a given marker performed best across all 342 genotyped batches and to remove systematically poor quality probesets. Ultimately, we retained 343 668,418 markers representing 97.34% of the original markers and included 459,777 samples from a total 344 of 485,856 unique genotyped samples in this data release. As expected, almost 98% of the markers that 345 were previously tested on the Axiom biobank array were associated with a probeset that passed quality 346 control, whereas 77% of the markers in the MVP 1.0 custom modules were associated with a probeset 347 that remained after quality control. Additionally, although sample missingness (the fraction of missing 348 genotype calls per individual; see Supplemental Materials and Methods) was slightly higher for Vendor 1 349 than for Vendor 2, almost all genotyped samples from both vendors exhibit missingness of less than 5% 350 ( Figure S6A ). 351
We also either excluded or quarantined samples that did not meet sample QC criteria. pairs could not be verified through independent means and were quarantined from data release as 360 potentially mislabeled and will be re-genotyped. We also cross-checked genetically determined sample 361 sex with EHR-reported gender information. Among the 485,856 unique genotyped samples, 2,000 362 (0.41%) did not have any reported gender information from either the EHR or self-report, and 2,073 363 (0.43%) of the remaining samples had a genetic sex that was opposite of the reported gender. We 364 quarantined these samples for further analysis and potential re-genotyping (Table S2 ). The total number 365 of samples that were excluded or quarantined from the current release of MVP genotype data and the 366 reasons for doing so are summarized in Table 1 . All quarantined samples removed from the current data 367 release will undergo further quality control validation, be sent back to the vendors for re-genotyping, or 368 will be otherwise verified before being included in subsequent data releases. 369 370 We assessed marker missingness in correlation with MAF. Overall, the MAF distribution of MVP 371 1.0 is highly skewed toward rare variants with 42.89% of markers below 1% MAF and 33.89% below 372 0.1% (Figure 2A ). This result is by design, as the content of the MVP array focuses on markers associated 373 with potential disease phenotypes. We find that MAF is correlated with marker missingness, as shown in 374 Figure 2C and Figure S6B , with lower frequency variants missing in a larger fraction of samples. Despite 375 this trend, missingness among low frequency markers is still relatively low. For example, 87.29% of rare 376 markers (MAF < 0.1%) are missing in less than 5% of genotype calls. 377
Marker missingness and discordance by MAF
Additionally, we examined marker genotype discordance rates across intentional duplicate 378 sample pairs with respect to MAF. Discordance is calculated per minor allele pair (MAP) for each marker, 379 and markers are binned by MAF. We find a correlation between MAF and discordance rate, with lower 380 frequency variants having a higher rate of minor allele discordance ( Figure 2B and Figure S6C) . 381
Duplicate and positive control samples for continuous quality assessment
382 Importantly, because we employed two separate vendors for genotyping, we intentionally 383 included 25,291 duplicate samples that were blinded to the vendors for independent assessment of 384 genotype quality. This amounts to a target of 5% of all genotyped samples and is an effort to accurately 385 assess genotyping quality on a continuous basis. Sample concordance among intentional duplicates or 386 positive controls was very high with a median concordance rate greater than 99.8% across all 387 comparisons ( Figure S7A were homozygous, 95,079 (14.46%) were heterozygous, and 18,689 (2.84%) were uncalled. 394
Concordance for each of the 2,064 positive controls samples is defined as the number of markers that 395 agree with the consensus sequence divided by the number of called markers in the consensus sequence. 396
Overall positive control concordance is shown in Figure S7A , and the distributions by batch of 397 concordance values across all positive controls are shown in Figure S7 B-D. The median concordance 398 rate between each positive control sample and the consensus sequence was 99.93% for all markers, 399 99.89% for common (MAF ≥5%) markers, and 100.00% for low frequency (MAF < 5%) markers. The 400 minimum observed concordance rate between a positive control and the consensus occurs when 401 analyzing common markers, but this concordance rate is still high at 99.05%. 402 removed from the numerator and denominator, the sample concordance across all population groups is 409 99.70% (Table 2) . Axiom® sample call rate for recommended markers is 99.85%. 410
Concordance with HapMap samples
Assessing rare allele genotyping quality 411 Given the importance of rare markers in clinically-related studies, we evaluated the analytical 412 validity of MVP 1.0 rare markers by observing the concordance of MAFs for rare markers with overlap 413 between MVP 1.0 and either the gnomAD or the UK Biobank (Figure 2 D-E) . These databases are large 414 enough for detection of very low MAFs, and agreement of MVP 1.0 marker MAFs with MAFs from these databases provides evidence for the accuracy of MVP 1.0 calls. MAFs were considered to agree when 416 the lower bound of the regression slope's 95% confidence interval was ≥ 0.9. This value leaves some 417 margin of error for expected differences between the databases in population structure Europeans vs. European Americans [EA]), technology (genotype arrays vs. exome sequencing), technical 419 processes (batch, user, etc.) , and sample size. We used the MVP EA subgroup to benchmark 420 performance because it has a larger sample size which provides better confidence in assessing 421 frequency of rare markers, and has large complementary subgroups in gnomAD and the UK Biobank. We 422 classified markers into three subgroups by MAF: rare variants (< 1%), low frequency variants (1-5%), and 423 common variants (>5%). The EA subgroup yielded 321,290 (48.1%) rare markers, 46,626 (6.97%) low 424 frequency markers, and 300,375 (44.9%) common markers. 425
From the gnomAD database, we compared the allele frequencies derived from the non-Finnish 426
European subgroup (N = 55,860) of the exome call set. This subgroup provided the largest cohort that 427 was comparable in population structure. In total, a majority of MVP rare variants were found in gnomAD 428 (69%, or 221,374 of 321,290 markers), and we found MAF agreement between MVP and gnomAD with a 429 slope of 0.9290 (95% CI: 0.9002, 0.9578). 430
From the UK Biobank, we compared allele frequencies derived from the self-reported white 431 British ancestry group (N > 330k). We found MAF agreement as supported by the strong coefficient of 432 determination (R 2 ) of 0.9864 and slope of 0.9536 (95%CI: 0.9841, 0.9887) between 46,872 overlapping 433
markers. 434
While comparison against both sources met the ≥ 0.9 agreement threshold, we observed a small 435 set of about 6000 extremely discrepant markers (defined as having MAF > 0.001 in one database but 436 MAF < 0.001 in the other) between MVP and gnomAD. About 53% of these markers were also present in 437 the UK Biobank. For these discrepant markers, MAFs in the UK Biobank were much closer to MVP MAFs 438 than those in gnomAD, and only one quarter of the overlapping UK Biobank markers retained the 439 "extremely discrepant" label. This is expected and consistent with previous observations that MAFs of 440 MVP and the UK Biobank are in close agreement. The extremely discrepant markers between MVP and 441 gnomAD may be attributed to the gnomAD-exome database having a smaller sample size than the UK 442 Biobank. The lowest MAF limit for MVP's EA subgroup is 1.6x10 -6 (1 of 622,730 total alleles), 8.9x10 -6 (1 443 of 111,720) for gnomAD's non-Finnish subgroup, and 1.4x10 -6 (1 of 674,398) for UK Biobank. At very low 444 frequencies, the absolute difference between rare variants, but not necessarily the relative difference, 445 will be small. A given marker with a MAF of 0.001 in MVP and 0.01 in gnomAD will have an absolute 446 difference of 0.009, but a relative difference of 10-fold. This is a common situation in our pairwise 447 marker comparisons since overlapping marker MAFs are heavily clustered near zero (Figure 2 D-E) . This 448 could also explain the relatively higher variance observed in the lower extremes when comparing MVP 449 against gnomAD versus against the UK Biobank. Overall, our results nonetheless show that our rare 450 variant calls are highly consistent and within a reasonable range of agreement with overlapping markers 451 in gnomAD and the UK Biobank. However, it is important to note that precision of very rare variants 452 assayed using SNP chips have been reported to show variable quality 21 . Thus, visual inspection of calls 453 underlying initial association results are always required. 454 Considering the samples that have already been genotyped, the MVP cohort is relatively more 463 diverse than other large biobanks on which data is available. For example, more than 94% of UK Biobank 464 participants self-report as British, Irish, or "any other white background" 4,12 , and the Kaiser RPGEH 465 biobank has 81% of samples reporting as "white, non-Hispanic". The MVP cohort on the other hand, has 466 70.9% of participants self-reporting as "white" and "non-Hispanic or Latino" and agrees with United 467
Population analysis of MVP samples and a test GWAS on height
States 2010 census information indicating 63.7% of respondents self-reporting as "White alone" and 468 "Not Hispanic or Latino" 22 . 469 Table  473 S8. Compared with the UK Biobank, this installment of MVP samples has a reduced fraction of related 474 pairs. 475
Analysis of relatedness
Analysis of genetic ancestry 476
Assessing genetic ancestry for genotyped samples is an important tool for many applications, 477 such as correcting for biases caused by population structure, constructing tests for natural selection, and 478 determining disease risk by genetic ancestry, among other tasks 23 . To assess genetic ancestry in our 479 sample, we visualized and then quantitatively assessed genetic ancestry of MVP samples relative to 480 external reference populations. 481
Runs of homozygosity (ROH) were measured using PLINK with a minimum ROH length of 1,000 482
Kb. The median total length of ROH is approximately 15.65 Mb, and the median number of blocks per 483 sample is 10. In Figure 3A , we plotted the total length of ROH per individual by genetic ancestry 484 subgroup for the five most common subgroups as defined in the Materials and Methods. MVP_GBR_PEL 485 samples have a wide distribution of total ROH length but also some of the longest total lengths of all 486 samples. Samples with African ancestry or admixed between three or more reference populations 487 (MVP_OTHER) have the shortest total length of ROH per sample. Samples of mainly European ancestry 488 have intermediate total ROH length. The total length of ROH per sample varies depending on the genetic 489 ancestry subgroup. 490
We also compared MVP samples to those in the 1000 Genomes Project. We first ran a PCA on 491 the 1000 Genomes Project phase 3 samples and then projected the MVP samples onto these PCs. We 492 find that most MVP samples lie close to reference populations of European origin. In addition, when we 493 performed PCA on MVP samples alone, we found that genetic ancestry subgroups contain more 494 complex intercontinental population structure, with a sizeable fraction of MVP samples exhibiting 495 admixture with respect to African and Asian references samples ( Figure 3B, Figure S9 ). 496
To assess ancestry proportion for each sample in MVP, we ran the program ADMIXTURE in 497 supervised mode using five 1000 Genomes Project Phase 3 reference populations: Han Chinese in 498
Beijing, China (CHB); British in England and Scotland (GBR); Luhya in Webuye, Kenya (LWK); Peruvians 499 from Lima, Peru (PEL); and Yoruba in Ibadan, Nigeria (YRI) 15 . Most participants have the largest 500 percentage of their genome aligning with the GBR population ( Figure S8C ). However, a substantial 501 fraction of samples contains a moderate amount of genetic ancestry similar to the YRI reference 502 population. Examples were also found of participants who have almost 100% of their genetic ancestry 503 aligning to each of the five reference populations except for LWK. Using ADMIXTURE analysis results, we 504 grouped the MVP samples into sixteen subgroups and determined the proportion of MVP samples 505 belonging to each ( Figure 3C ). For example, 326,777 samples have over 80% of their genome aligning 506 with the GBR reference population (MVP_GBR) whereas 58,267 samples have 80% or more of their 507 genome aligning with YRI (MVP_YRI). Excluding samples with more than 80% of their genome aligning to 508 one reference population, 25,295 of the samples have 90% or more of their genome aligning with a 509 combination of GBR and YRI reference populations (MVP_GBR_YRI). Approximately 16,351 samples 510 (MVP_OTHER) have neither 80% of their genome aligning with one reference population nor 90% 511 aligning with a combined pair, indicating substantial admixture between three or more reference 512 populations. 513
Finally, we visualized the diverse ancestry composition of MVP using a non-parametric 514 dimensionality reduction method called UMAP ( Figure 3D ). As shown through PCA and ADMIXTURE, the 515 largest cluster corresponds to samples with largely European ancestry. In this visualization, the distance 516 between samples and clusters is not to be directly interpreted as genetic distance. Although there are 517 distinct clusters (such as individuals with Asian ancestry forming a tight cluster within themselves on the 518 top left corner, and another small cluster of likely Polynesians in the middle of the plot), most MVP 519 samples of different ancestries form a large single cluster rather than clusters with distinct breaks. This 520 large cluster shows a continuum of ancestry proportion that transitions from GBR on the top right to 521 different levels of admixture with YRI and PEL proportions. This is in line with a previous report based on 522 32,000 US individuals in the National Geographic Genographic Project cohort 24 . 523
GWAS of height 524
To further validate the quality of our genotype data and the utility of MVP 1.0 array, we 525 conducted a GWAS of height in both the EA and African American (AA) MVP subpopulations. EAs were 526 defined as individuals with greater than 90% GBR proportion, and AA were defined as individuals with 527 greater than 60% YRI and less than 40% GBR based on ADMIXTURE results (Figure S8 A-B ). Our GWAS of 528 height within EA and AA cohorts showed moderate inflation of λGC=1.12 and λGC=1.13, with pseudo-529 heritability of 0.396 and 0.378, respectively 19, 25, 26 , a level comparable to previous association studies in 530 height without genotype imputation 27 . 531
Of the 822 reported associations with height listed in the GWAS catalog 28 , 230 were present in 532 the MVP EA GWAS, and 209 were present in the MVP AA GWAS. We assessed whether we could replicate effect sizes and direction of effects for markers present in MVP EA and AA GWAS by plotting 534 these against the GWAS catalog effect sizes and direction of effects (Figure 4 ). For the two 535 subpopulations, the MVP associations perfectly replicated the directions of effect in most markers (two 536 SNPs had near 0 effect size in EA). However, as most GWAS catalog associations are derived from 537 Europeans, the overall correlation across all markers was lower for the AA cohort (r=0.69) compared to 538 the EA cohort (r=0.85). 539
Overall, we show that the performance of MVP 1.0 and the quality of its genotyping across 540 459,777 individuals of diverse ethnic background is very consistent and accurate by a variety of metrics. 541
Discussion
542
In this report, we provide an overview of the design of the MVP 1.0 genotyping array, the 543 development of accompanying quality control analyses, and of our initial data exploration of an interim 544 MVP genotyping dataset that consists of nearly 460,000 Veterans. Our results demonstrate that the 545 MVP 1.0 chip and the subsequent QC procedures have addressed notable challenges characteristic of 546 large projects with individuals of diverse genetic background, and that the resulting genotype calls is of 547 high-quality akin to other projects similar in scope. By using a single chip and unified quality control 548 across the diverse cohort, we aimed to minimize batch effects between different ancestries and provide 549 an initial genome-wide scan before whole genome sequenced samples become available. 550
Addressing the challenges of MVP 551 MVP's large, diverse and still-growing cohort poses numerous challenges for designing 552 genotyping procedures and their subsequent quality assessment/quality control protocols. Genotyping 553 large and ethnically diverse cohorts along with clinically relevant markers is even more challenging due 554 to the finite number of probesets that can fit on a single array. However, using different arrays for 555 different ethnic groups can also exacerbate the differences between these groups and lead to batch 556 effects. 557
To address the limitations of array-based genotyping in diverse cohorts, we carefully selected 558 array content to maximize clinical utility while at the same time ensuring both broad coverage of 559 variants and robust imputation capabilities across different ethnic groups. We also developed 560 comprehensive quality controls for markers and samples both before and after genotyping, including: 561 intentional duplication of ~5% randomly selected samples over time, blinded to assay technicians, to 562 detect and mitigate batch variation; assessment of genotyping concordance using positive control 563 samples and HapMap samples ( Figure S7A , Table 2 ); comparing MVP 1.0 MAFs to those in gnomAD and 564 the UK Biobank ( Figure 2) ; and conducting a GWAS of height to replicate previously reported results 565 ( Figure 4) . Overall, we retained and released 459,777 samples and 668,418 markers after QC for the 566 initial release of data. Although QC metrics vary slightly over time and genotyping vendors, the final 567 genotyped sample set show consistently high call rates (98.5%) and genotype concordance over 568 intentional duplicates (99.8%) both within and between vendors and over time. Furthermore, marker 569 concordance is also high even for rare markers. Additionally, genotype concordance, MAF, and GWAS 570 association results are generally in strong agreement with external or previously reported results. These 571 results indicate that the design of the MVP 1.0 array and the associated quality control and assessment 572 procedures provide a robust, reliable method for both genotyping common, low-frequency, and rare 573 variants in a large, ethnically diverse cohorts. 574
Challenges remain, however, and the MVP 1.0 array has several limitations. Notably, although 575 concordance rates were high, our results demonstrate that low-frequency and rare variants are still 576 more difficult than common variants to genotype accurately using the MVP 1.0 array. Additionally, while 577 we added markers to MVP 1.0 to increase coverage for African Americans, we lack boosters for other 578 ethnic groups, such as Asian and Native American populations, which currently comprise smaller but 579 growing proportions in the MVP population. 580
The MVP dataset is ethnically and genetically diverse Approximately 8.5% of MVP samples are female, which is similar to the fraction of women in the 590 Veteran population 29 . MVP participants are also substantially older than the United States population 591 with a median age of 68 as opposed to 37.9 years 30 . However, the demographics of MVP may change 592 with increasing use of the VA by more recent Veterans who have completed their service. The 593 proportion of female Veterans is projected to continuously grow and nearly double to 16.5% by 2043 29 . 594
Meanwhile, the proportion of Veterans from minority populations is expected to increase by 595 approximately 50% over the same time period 29 . Thus, the VA and MVP is in a unique position for 596 further inclusion of participants from diverse backgrounds. 597
The MVP dataset is an invaluable disease research resource 598 MVP has several unique features that make it an invaluable resource for human disease 599 research. As evidence of the general utility of this resource, initial reports using an earlier tranche of 600 ~300,000 genotyped participants have reported substantial new findings regarding the genetics of blood 601 lipids, a major cardiovascular risk factor 31 . Not only is MVP ideal for studying the burden of chronic 602 disease, which increases with age, many of the clinical records in its EHR span several decades, allowing 603 for robust longitudinal analysis. This is possible as patients using the VA health services do not lose 604 coverage even after changing employers or residence. Additionally, MVP provides an opportunity to 605 study diseases disproportionately affecting US veterans, such as PTSD 32 , alcohol and substance abuse 606 disorders 33 , as well as other deployment-related conditions and their impact on human health. 607
In conclusion, the high-quality genotype data generated using the MVP 1.0 array provides a 608 valuable resource for researchers investigating the effect of both rare and common genetic variants 609 within MVP. This quality-controlled genotype data as well as the results from genetic ancestry and 610 relatedness analyses are made available to all approved researchers. The genotype data can be linked to 611 the full EHR of participants, often covering decades of care provided by the VA. MVP is a continuously 612 expanding research cohort made available by participants with diverse backgrounds and altruistic 613 intentions to support research that will benefit their fellow Veterans and others. 614 
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